--- title: "Cagrilintide: what sources report" url: https://humanpeptides.fyi/peptides/cagrilintide site: humanpeptides.fyi last_reviewed: 2026-10-11 --- # Cagrilintide > humanpeptides.fyi makes no claims of its own. Every statement below reports what a cited source says, with its link. Not medical advice. Cagrilintide: Long-acting once-weekly amylin analogue (amylin/calcitonin receptor agonist) from Novo Nordisk that reduces appetite. The sources cited here most often discuss it for: Weight loss; Bigger results with semaglutide; Quieter food noise. Evidence label: Trial-backed. ## At a glance - **Type:** Peptide - **Family:** Weight & Metabolic - **Evidence label:** Trial-backed (4 of 5) - **Regulatory status:** CagriSema (cagrilintide plus semaglutide) is not FDA-approved; Novo Nordisk submitted its application in December 2025, and the company expects an FDA decision in the fourth quarter of 2026. - **Goals discussed:** Fat Loss & Metabolism, Calm & Mood - **Also called:** AM833, NN 9838, NNC-0174-0833, Cag, Cagri - **Last reviewed:** 2026-10-11 ## What is Cagrilintide? - Long-acting once-weekly amylin analogue (amylin/calcitonin receptor agonist) from Novo Nordisk that reduces appetite; investigational, not FDA-approved alone; combo with semaglutide (CagriSema) filed with FDA Dec 2025, decision expected Q4 2026. )01751-7/abstract Sources: , Most large trial results, including the REDEFINE program, are for CagriSema, a fixed combination of cagrilintide with semaglutide, not cagrilintide alone. **Regulatory status:** CagriSema (cagrilintide plus semaglutide) is not FDA-approved; Novo Nordisk submitted its application in December 2025, and the company expects an FDA decision in the fourth quarter of 2026. Source: ## What is Cagrilintide researched for? ### 1. Weight loss - Weight loss: phase 2 (n=706, 26 wk) dose-dependent loss of 6.0-10.8% vs 3.0% placebo; 4.5 mg (10.8%) beat liraglutide 3.0 mg (9.0%) (human RCT) Sources: , - Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss) ### 2. Bigger results with semaglutide - With semaglutide (CagriSema): REDEFINE 1 phase 3 (n=3,417, 68 wk) mean weight loss 20.4% vs 3.0% placebo; 34.7% lost >=25%; mostly fat mass lost (human phase 3 RCT) Sources: , - Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss) ### 3. Quieter food noise - Reduced 'food noise' and appetite (CagriSema EASD 2026 data; Reddit users describe strong appetite suppression at varying doses) (human trial + anecdotal) Sources: , - Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss), [Calm & Mood](https://humanpeptides.fyi/objectives/mood) ## What do researchers and users say about Cagrilintide? > "Treatment with cagrilintide in people with overweight and obesity led to significant reductions in bodyweight and was well tolerated." > > Lau DCW, et al., Once-weekly cagrilintide for weight management in people with overweight and obesity (The Lancet, 2021). Context: 26-week phase 2 dose-finding RCT of cagrilintide alone in 706 adults (cagrilintide, liraglutide and placebo arms), funded by Novo Nordisk. > "after 52 weeks, across all measures of appetite and eating behaviour, people with overweight and obesity had substantially reduced food cravings and sustained changes in the brain response to viewing pictures of high-calorie foods" > > Prof. Tony Goldstone, Imperial College London, Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears (Medical Daily, 2026). Context: Comment in Novo Nordisk's EASD 2026 announcement of a 52-week brain-scan study of CagriSema (cagrilintide + semaglutide); not yet peer reviewed. > "For me it has been the first peptide to absolutely smoke my hunger." > > Anonymous user, r/Biohacking, cagrilintide experience ?. Context: User report in a cagrilintide experience thread; the user was also taking retatrutide. ## What side effects of Cagrilintide are reported? - Nausea and other GI effects, dose-escalation dependent; 10.3% discontinued in phase 2; CagriSema GI events in 79.6%, mostly mild-moderate and transient (human RCTs) )01751-7/abstract Sources: , - Fatigue commonly reported by users (anecdotal) Sources: - Injection-site (administration-site) reactions were among the most frequent adverse events with cagrilintide alone (human RCT) Sources: - With CagriSema in REDEFINE 1: nausea 55%, constipation 30.7% and vomiting 26.1%, versus 12.6%, 11.6% and 4.1% with placebo (human RCT, company release) Sources: - Users describe feeling flat, unmotivated or weak (anecdotal) Sources: - Small heart-rate increases, and rare pancreatitis or gallbladder problems, flagged as possible concerns shared with other weight-loss drugs (theoretical, education site) Sources: ## What do peptide guides say about Cagrilintide? - **PepEdHub:** PepEdHub explains that cagrilintide activates amylin receptors in the brain's area postrema to reduce appetite, slow stomach emptying and suppress glucagon, complementing semaglutide in the CagriSema combination. - **Seek Peptides:** Seek Peptides flags fatigue, affecting roughly one in five phase 2 participants by its account, as an overlooked side effect, and lists open questions about long-term gallbladder, antibody and bone effects. - **NCBI PMC:** In obese mice, cagrilintide's weight loss depended on brain amylin receptors AMY1 and AMY3; mice lacking the RAMP1 and RAMP3 receptor components responded less. - **BioPharma Dive:** In an 84-week head-to-head phase 3 trial, CagriSema produced about 20% average weight loss versus about 24% with Lilly's Zepbound, too large a gap to declare it non-inferior. ## What does the research say, system by system? ### Body & tissues - CagriSema reported benefits in organ and bone health at EASD 2026 (company release) Sources: ### Hormones & physiology - Amylin-pathway satiety hormone mimic; CagriSema also lowered blood pressure and waist circumference (human RCT) Sources: - Phase 3 data in type 2 diabetes presented ADA 2026 Sources: ### Brain, mood & sleep - Acts on brain appetite centres; reduced food noise (human trial, company release) Sources: ### Weight & metabolism - 6-10.8% loss alone at 26 wk; ~20% with semaglutide at 68 wk (human RCTs) )01751-7/abstract Sources: , ### Muscle - In REDEFINE 1, fat-mass loss predominated over lean mass (human RCT body composition substudy) Sources: ### Also notable - Grey-market 'research' cagrilintide widely used on Reddit, often stacked with retatrutide/semaglutide (anecdotal) Sources: ## How strong is the evidence for Cagrilintide? **Trial-backed** (4 of 5). Strong human RCT data (phase 2 alone, phase 3 with semaglutide); not yet FDA-approved _Larger randomized human trials exist, positive or negative, but no US approval for the uses discussed._ ## Street names and stacks - Street names: [Cagri](https://humanpeptides.fyi/street-names#nick-cagri) ## Questions about Cagrilintide ### What is Cagrilintide? Long-acting once-weekly amylin analogue (amylin/calcitonin receptor agonist) from Novo Nordisk that reduces appetite. Most large trial results, including the REDEFINE program, are for CagriSema, a fixed combination of cagrilintide with semaglutide, not cagrilintide alone. ### Is Cagrilintide FDA-approved? CagriSema (cagrilintide plus semaglutide) is not FDA-approved; Novo Nordisk submitted its application in December 2025, and the company expects an FDA decision in the fourth quarter of 2026. ### What is Cagrilintide researched for? The sources cited on this page most often discuss three outcomes: Weight loss; Bigger results with semaglutide; Quieter food noise. Each line above shows what the source reports and how strong that evidence is. ### What side effects of Cagrilintide are reported? Reported in the cited sources: Nausea and other GI effects, dose-escalation dependent; 10.3% discontinued in phase 2; CagriSema GI events in 79.6%, mostly mild-moderate and transient (human RCTs) )01751-7/abstract; Fatigue commonly reported by users; Injection-site (administration-site) reactions were among the most frequent adverse events with cagrilintide alone. The list is not complete, and few listed risks does not mean a compound is safe. ### How strong is the evidence for Cagrilintide? Evidence label: Trial-backed. Strong human RCT data (phase 2 alone, phase 3 with semaglutide); not yet FDA-approved. ### What else is Cagrilintide called? Names used for it include AM833, NN 9838, NNC-0174-0833, Cag, Cagri. ### Does humanpeptides.fyi recommend Cagrilintide? No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician. --- Family: [Weight & Metabolic](https://humanpeptides.fyi/peptides?cat=metabolic). HTML version: . Disclaimer: